Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745515 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL9218563 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL6545054 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL5067829 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| Hydrochloric Acid SCHEMBL2495103 | 0.98 | CD274 (0.49) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL27508562 | 0.88 | MAOA (0.62) | GRM6MAOAMAOBMAPTKDM4E | |
| SCHEMBL1162855 | 0.88 | MAOA (0.62) | GRM6MAOAMAOBMAPTKDM4E | |
| SCHEMBL18347538 | 0.86 | MAPT (0.55) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL24938939 | 0.85 | CYP3A4 (0.50) | MAOAMAOBMAPTKDM4E | |
| SCHEMBL4249938 | 0.85 | CYP3A4 (0.50) | MAOAMAOBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-10851099-B2 | Dipeptide piperidine derivatives | Oncoarendi Therapeutics S.A. (PL) | 2020-12-01 | — | — | US | disclosed |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| EP-0711755-B1 | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists | LILLY CO ELI (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1996015108-A1 | PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0711755-A1 | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-05-15 | — | — | EP | disclosed |
| US-5473077-A | 4-aminopyrrolidine-2,4-substitude independently with carboxylic acid or 5-tetrazolyl for treating nervous system disorders and psychological disorders | ELI LILLY AND COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851099-B2 | Dipeptide piperidine derivatives | ARG1, ARG2, PEPD | CD274 3794/4885GRM6 2505/4885MAOA 2821/4885 |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | ARG1, ARG2, PEPD | CD274 3794/4885GRM6 2505/4885MAOA 2821/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CD274 92/4885GRM6 3168/4885MAOA 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.